Mild cognitive impairment as a clinical entity and treatment target

Archives of Neurology

Volumn 62, Issue 7, 2005, Pages 1160-1163

  Petersen, Ronald C ^a   Morris, John C ^b  

^a Mayo Clinic   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; AMNESIA; CLINICAL EXAMINATION; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; HUMAN; MEMORY; MILD COGNITIVE DEFECT; NERVE DEGENERATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; SYMPTOM; TREATMENT PLANNING; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; MEMORY DISORDER; NOTE; REFERENCE VALUE; RISK FACTOR;

COGNITION DISORDERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; MEMORY DISORDERS; REFERENCE VALUES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 22844444303     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.7.1160     Document Type: Review

References (27)

1. Petersen RC. Mild cognitive impairment. Continuum. 2004;10:9-28.
2. Petersen RC, ed. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York, NY: Oxford University Press; 2003.
3. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006-1009.
4. Gauthier S, Touchon J. Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005;62:1164-1166.
5. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
7. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198-205.
8. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179-1184.
9. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115-121.
10. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594-1599.
11. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56:37-42.
12. Unverzagt FW, Gao S, Baiyewu O, et al. Prevalence of cognitive impairment: data from the Indianapolis Study of Health and Aging. Neurology. 2001;57:1655-1662.
13. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
14. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer's disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
15. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov. 2003;2:646-653.
16. Petersen RC, Thomas RG, Grundman M, et al. Donepezil and vitamin E in the treatment of mild cognitive impairment. N Engl J Med. In press.
17. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus. J Intern Med. 2004;256:240-246.
18. Storandt M, Grant EA, Miller PJ, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer disease. Neurology. 2002;59:1034-1041.
19. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol. 2001;58:397-405.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
21. Dik MG, Jonker C, Bouter LM, Geerlings MI, van Kamp GJ, Deeg DJ. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology. 2000;54:1492-1497.
22. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
23. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397-1403.
24. Korf ES, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94-100.
25. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49:202-213.
26. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972-976.
27. DeKosky ST, Ikonomovic M, Styren S, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.